GENFIT (GNFT.PA)
FR0004163111 - Common Stock
Overall GNFT gets a fundamental rating of 5 out of 10. We evaluated GNFT against 75 industry peers in the Biotechnology industry. GNFT has an average financial health and profitability rating. GNFT is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
GNFT had positive earnings in the past year.
GNFT had a negative operating cash flow in the past year.
GNFT had negative earnings in 4 of the past 5 years.
In the past 5 years GNFT reported 4 times negative operating cash flow.
1.2 Ratios
GNFT has a Return On Assets of 11.43%. This is amongst the best in the industry. GNFT outperforms 98.57% of its industry peers.
GNFT's Return On Equity of 22.87% is amongst the best of the industry. GNFT outperforms 95.71% of its industry peers.
GNFT's Return On Invested Capital of 11.07% is amongst the best of the industry. GNFT outperforms 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| ROIC | 11.07% |
ROA(3y)-1.25%
ROA(5y)-15.15%
ROE(3y)-3.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of GNFT (26.51%) is better than 95.71% of its industry peers.
With an excellent Operating Margin value of 28.39%, GNFT belongs to the best of the industry, outperforming 95.71% of the companies in the same industry.
Looking at the Gross Margin, with a value of 97.41%, GNFT belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
In the last couple of years the Gross Margin of GNFT has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.39% | ||
| PM (TTM) | 26.51% | ||
| GM | 97.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5Y4.62%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), GNFT is creating some value.
Compared to 1 year ago, GNFT has about the same amount of shares outstanding.
Compared to 5 years ago, GNFT has more shares outstanding
GNFT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.01, we must say that GNFT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.01, GNFT perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
GNFT has a Debt/Equity ratio of 0.61. This is a neutral value indicating GNFT is somewhat dependend on debt financing.
GNFT's Debt to Equity ratio of 0.61 is on the low side compared to the rest of the industry. GNFT is outperformed by 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.01 |
ROIC/WACC1.54
WACC7.2%
2.3 Liquidity
A Current Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
GNFT has a better Current ratio (3.74) than 68.57% of its industry peers.
A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.74, GNFT is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
GNFT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 153.62%, which is quite impressive.
GNFT shows a strong growth in Revenue. In the last year, the Revenue has grown by 182.34%.
The Revenue has been growing by 38.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)153.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.19%
Revenue 1Y (TTM)182.34%
Revenue growth 3Y70.09%
Revenue growth 5Y38.49%
Sales Q2Q%413.61%
3.2 Future
The Earnings Per Share is expected to grow by 25.73% on average over the next years. This is a very strong growth
GNFT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.66% yearly.
EPS Next Y379.58%
EPS Next 2Y-69.7%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year54.53%
Revenue Next 2Y-23.27%
Revenue Next 3Y-11.25%
Revenue Next 5Y27.66%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.95, which indicates a very decent valuation of GNFT.
95.71% of the companies in the same industry are more expensive than GNFT, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 29.48. GNFT is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.95 | ||
| Fwd PE | N/A |
4.2 Price Multiples
94.29% of the companies in the same industry are more expensive than GNFT, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.39 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GNFT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as GNFT's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y-69.7%
EPS Next 3Y25.73%
5. Dividend
5.1 Amount
No dividends for GNFT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENFIT
EPA:GNFT (12/6/2024, 7:00:00 PM)
3.68
+0.02 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap183.49M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.95 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.03
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 28.39% | ||
| PM (TTM) | 26.51% | ||
| GM | 97.41% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)153.62%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y379.58%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)182.34%
Revenue growth 3Y70.09%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y